Tailored Antiplatelet Therapy Following PCI (TAILOR-PCI)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01742117 |
|
Recruitment Status :
Recruiting
First Posted : December 5, 2012
Last Update Posted : November 21, 2017
|
Sponsor:
Mayo Clinic
Collaborators:
Spartan Bioscience Inc.
Applied Health Research Centre
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Naveen L. Pereira, Mayo Clinic
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration (FDA) for use in patients who undergo Percutaneous Coronary Intervention (PCI) with coronary stent implantation. Anti-platelet medications work to prevent blood clots from forming. Some studies have suggested that patients who have a certain genetic liver enzyme abnormality (known as cytochrome P450 2C19 [CYP2C19] *2 or *3 allele) may have a reduced ability to activate clopidogrel, and therefore may have a lowered response to clopidogrel. It is thought that perhaps people who have a coronary stent procedure may have this genetic liver enzyme abnormality. There is a research genetic test available to determine whether or not someone has this genetic liver enzyme abnormality. Ticagrelor, is a newer anti-platelet drug that is not dependent on the CYP2C19 liver enzyme for its activation and hence in poor clopidogrel metabolizers, alternative drugs like Ticagrelor have been recommended for use as an anti-platelet agent after PCI. The purpose of this study is to determine if genetic testing can identify the best anti-platelet therapy, for patients who undergo a coronary stent placement and do not activate clopidogrel very well.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Coronary Artery Disease Acute Coronary Syndrome Stenosis | Drug: Clopidogrel Drug: Ticagrelor Genetic: Retrospective Genotype testing Genetic: Prospective Genotype testing | Phase 4 |
TAILOR-PCI is a multi-site, open label, prospective, randomized trial testing the hypothesis that after percutaneous coronary intervention (PCI), using a genotyping strategy ticagrelor 90 mg twice per day is superior to clopidogrel 75 mg per day in reducing a composite endpoint of major adverse cardiovascular events (MACE), i.e., non-fatal myocardial infarction, non-fatal stroke, severe recurrent ischemia, cardiovascular (CV) death, and stent thrombosis (primary endpoints) in CYP2C19 reduced function allele patients. Patients who undergo PCI will be randomized to a conventional therapy arm (i.e., to receive clopidogrel 75 mg once daily without prospective genotyping guidance) versus a prospective CYP2C19 genotype-based anti-platelet therapy approach (ticagrelor 90 mg bid in CYP2C19 *2 or *3 reduced function allele patients, clopidogrel 75 mg once daily in non-*2 or -*3 CYP2C19 patients). Buccal swabs will be obtained for those subjects randomized to the prospective genotyping arm. All subjects will have a blood sample drawn for DNA analysis but genotyping using these DNA samples will be performed only after completion of the duration of anti-platelet therapy (i.e., after one year). The primary endpoints will be assessed prospectively and will be compared between the conventional arm and the prospective genotyping arm among those identified as reduced function CYP2C19 allele carriers according to the 1-year genotype results.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 5270 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI) |
| Study Start Date : | May 2013 |
| Estimated Primary Completion Date : | September 2019 |
| Estimated Study Completion Date : | March 2020 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Clopidogrel then Retrospective Genotyping
Clopidogrel 75 mg daily for 1 year after PCI. DNA samples at baseline to be frozen. At 12 months DNA will be genotyped to determine the *2 & *3 reduced function/wild type allele status.
|
Drug: Clopidogrel
Subjects will receive Clopidogrel, one 75 mg tablet per day by mouth for one year.
Other Name: Plavix Genetic: Retrospective Genotype testing Mayo Clinic will use ABI TaqMan assay of three variants in the CYP2C10 gene: *2, *3 and *17 |
|
Active Comparator: Prospective Genotyping - Clopidogrel
Patients with the wild type CYP2C19 allele (based on prospective genotype testing) will be assigned to receive a clopidogrel 75mg tablet daily for 1 year following PCI.
|
Drug: Clopidogrel
Subjects will receive Clopidogrel, one 75 mg tablet per day by mouth for one year.
Other Name: Plavix Genetic: Prospective Genotype testing Rapid turnaround Spartan^TM Bioscience in vitro diagnostic assay for analysis of three variants in the CYP2C19 gene: *2, *3 and *17 |
|
Active Comparator: Prospective Genotyping - Ticagrelor
Patients with the CYP2C19 heterozygous and homozygous *2 and *3 reduced function allele (based on prospective genotype testing) will be assigned to receive a ticagrelor 90 mg tablet twice per day for one year following PCI.
|
Drug: Ticagrelor
Subjects will receive Ticagrelor, one 90 mg tablet twice per day by mouth.
Other Name: Brilinta Genetic: Prospective Genotype testing Rapid turnaround Spartan^TM Bioscience in vitro diagnostic assay for analysis of three variants in the CYP2C19 gene: *2, *3 and *17 |
Primary Outcome Measures :
- Occurrence of the a major adverse cardiovascular event (MACE) [ Time Frame: Randomization, one year after percutaneous coronary intervention (PCI) ]MACE will include non-fatal myocardial infarction, non-fatal stroke, cardiovascular mortality, severe recurrent ischemia, and stent thrombosis
Secondary Outcome Measures :
- Number of subjects with reduced function CYP2C19 allele(s) who have major or minor bleeding [ Time Frame: One year after PCI ]Includes subjects who have bleeding events
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion
- Patient >18 years of age
- Patient presents with acute coronary syndrome (ACS) or stable coronary artery disease (CAD)
- Patient is eligible for PCI
- Patient is willing and able to provide informed written consent
5.3 Exclusion
- Patient not able to receive 12 months of dual anti-platelet therapy
- Failure of index PCI
- Patient or physician refusal to enroll in the study
- Patient with known CYP2C19 genotype prior to randomization
- Planned revascularization of any vessel within 30 days post-index procedure and/or of the target vessel(s) within 12 months post-procedure
- Anticipated discontinuation of clopidogrel or ticagrelor within the 12 month follow up period, example for elective surgery
- Serum creatinine >2.5 mg/dL within 7 days of index procedure
- Platelet count <80,000 or >700,000 cells/mm3, or white blood cell count <3,000 cells/mm3 if persistent (at least 2 abnormal values) within 7 days prior to index procedure.
- History of intracranial hemorrhage
- Known hypersensitivity to clopidogrel or ticagrelor or any of its components
- Patient is participating in an investigational drug or device clinical trial that has not reached its primary endpoint
- Patient previously enrolled in this study
- Patient is pregnant, lactating, or planning to become pregnant within 12 months
- Patient has received an organ transplant or is on a waiting list for an organ transplant
- Patient is receiving or scheduled to receive chemotherapy within 30 days before or after the procedure
- Patient is receiving immunosuppressive therapy or has known immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematous, etc.)
- Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor)
- Concomitant use of simvastatin/lovastatin > 40 mg qd
- Concomitant use of potent CYP3A4 inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine)
- Non-cardiac condition limiting life expectancy to less than one year, per physician judgment (e.g. cancer)
- Known history of severe hepatic impairment
- Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
- Patient has an active pathological bleeding, such as active gastrointestinal (GI) bleeding
- Inability to take aspirin at a dosage of 100 mg or less
- Current substance abuse (e.g., alcohol, cocaine, heroin, etc.)
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01742117
Contacts
| Contact: Monica Olson | 507-255-2649 | rstTAILORPCI@mayo.edu |
Show 40 Study Locations
Sponsors and Collaborators
Mayo Clinic
Spartan Bioscience Inc.
Applied Health Research Centre
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
| Principal Investigator: | Naveen Pereira, MD | Mayo Clinic | |
| Principal Investigator: | Michael E Farkouh, MD | Toronto General Hospital | |
| Principal Investigator: | Kent R Bailey, PhD | Mayo Clinic |
| Responsible Party: | Naveen L. Pereira, Professor of Medicine, College of Medicine, Mayo Clinic |
| ClinicalTrials.gov Identifier: | NCT01742117 History of Changes |
| Other Study ID Numbers: |
11-006837 5U01HL128606 ( U.S. NIH Grant/Contract ) |
| First Posted: | December 5, 2012 Key Record Dates |
| Last Update Posted: | November 21, 2017 |
| Last Verified: | November 2017 |
Keywords provided by Naveen L. Pereira, Mayo Clinic:
|
percutaneous coronary intervention angioplasty |
Additional relevant MeSH terms:
|
Coronary Artery Disease Myocardial Ischemia Coronary Disease Acute Coronary Syndrome Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Clopidogrel Ticlopidine Ticagrelor Platelet Aggregation Inhibitors |
Purinergic P2Y Receptor Antagonists Purinergic P2 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Fibrinolytic Agents Fibrin Modulating Agents Cytochrome P-450 CYP2C19 Inhibitors Cytochrome P-450 Enzyme Inhibitors Enzyme Inhibitors |